Coronavirus disease-2019 (COVID-19) pneumonia is one of the severe and most dreaded forms of illness caused by severe acute respiratory syndrome coronavirus 2. It often progresses to respiratory failure and acute respiratory distress syndrome (ARDS) requiring mechanical ventilation. ARDS can lead to multiple complications while on mechanical ventilation due to positive airway pressures in a fibrotic lung, one such complication is the development of alveolopleural fistula. Alveolopleural fistula has high morbidity and mortality. We used endobronchial valve in a patient with COVID-19-related ARDS with persistent air leak (alveolopleural fistula), which allowed us to remove the chest tube and wean the patient successfully off mechanical ventilation.
Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) has many potential complications though most occur infrequently. We encountered a case in which the EBUS needle broke during TBNA. The patient was a 65 year old man who underwent EBUS-TBNA for right paratracheal lymphadenopathy. During the procedure, the TBNA needle was found to be broken. We were able to completely recover it without any complications to the patient or to the EBUS scope.
Introduction: Coronavirus Disease 2019 (COVID 19) is a viral illness caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). We report a patient with COVID-19 pneumonia leading to ARDS and subsequent development of an alveolopleural fistula who was successfully treated with multiple endobronchial valves. Case: The Patient was a 55-year-old Hispanic male who presented with 2 days of dry cough and shortness of breath. Vital signs on admission showed an oxygen saturation of 68% on ambient air and respiratory rate of 30 breaths per minute. He was admitted with acute hypoxic respiratory failure and found to have a positive SARS-Cov2 infection. Initial CT chest without contrast showed diffuse bilateral ground-glass opacities. His oxygen requirement increased as well as his work of breathing requiring BiPAP, and subsequent intubation. On the 10th day of admission, he developed a right-sided pneumothorax, requiring chest tube placement. A tracheostomy was completed on day 14 for further ventilator weaning. On day 20, he developed persistent air leak concerning for an alveolopleural fistula, repeat CT chest concerning for a moderate-sized pneumothorax and findings concerning for post ARDS fibrotic lungs. He continued to have persistent air leak but was not deemed to be a surgical candidate hence he was referred for endobronchial valve placement to facilitate chest tube removal and ventilator weaning. Bronchoscopy was done on day 41 of admission. Total 6 endobronchial valves were placed (right middle and lower lobes). Over next few days his leak completely resolved. Patient was weaned off of positive pressure a week later to trach collar, and the chest tube was subsequently removed. Discussion: Alveolopleural fistula is a communication or fistula between a alveoli and the pleural space. Patient's with ARDS secondary to COVID-19 requiring high amounts of PEEP and are at higher risk in developing a pneumothorax. Endobronchial valves (EBV) have been used since 2005 to treat alveolopleural and bronchopleural fistula in patients who are not considered a good surgical candidate. This is the first documented use of an EBV in the setting of COVID-19 that we could find. The placement of the valves, allowed a significant reduction in the air leak. This assisted in the patient's breathing trials on the ventilator and tracheostomy collar trials by reducing the overall volume loss through the fistula, ultimately allowing the patient to successfully liberated from the ventilator and have his chest tubes removed.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.